Recommend Human Vaccines to your librarian for 2008. Download form here.
Email this page
Print this page
Research Paper
The Immunogenicity and Reactogenicity of a New DTPw-HBV Vaccine as a Primary and Booster Vaccination Dourse in Healthy Infants
Roman Prymula, Marie-Pierre David, Inge Lefevre and Igor Kohl
volume 3 | issue 4
july/augustPages: 121 - 126
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
The immunogenicity and reactogenicity of primary vaccination at 3, 4 and 5 months and boosting at 12-18 months with a new DTPw-HBV vaccine was compared with either licensed DTPw and HBV vaccines given separately or a licensed DTPw-HBV combination (Tritanrix™ HepB) in this randomised, partially double-blind primary vaccination and single-blind booster vaccination study in healthy infants (n=239; Trial DTPw-HBV-001/004). One month after primary vaccination with the new DTPw-HBV vaccine, seroprotection against diphtheria, tetanus, hepatitis B and vaccine response to B. pertussis was seen in 100%, 98.7%, 94.9% and 98.7% of subjects, respectively, compared to 100%, ≥98.5%, 89.2% and 92.2% of subjects in the comparator groups, respectively. One month after the booster dose, a marked response to all vaccine antigens was observed, resulting in seroprotection against diphtheria, tetanus, hepatitis B in all DTPw-HBV recipients and response to B. pertussis in over 98.6%. After primary vaccination, there was evidence that fever ≥ 38.0°C (rectal route) occurred more frequently after the new vaccine (following 41.6% of doses, compared with 32.2% and 29.3% in the comparator groups, p<0.05) and that pain and drowsiness occurred more frequently than after licensed DTPw-HBV (45.3% versus 35.1% and 37.1% versus 24.9%, respectively). However after primary and booster doses Grade 3 symptoms occurred at similar frequencies in the three groups suggesting these possible differences are of minimal clinical significance. In conclusion, within the framework of this study the immunogenicity and safety profiles of GSK Biologicals’ new DTPw-HBV vaccine when used for primary and booster vaccination were acceptable.
Authors
Roman Prymula
University of Defense; Hradec Kralove, Czech Republic
Marie-Pierre David
GlaxoSmithKline Biologicals; Rixensart, Belgium
Inge Lefevre
GlaxoSmithKline Biologicals; Rixensart, Belgium
Igor Kohl
GlaxoSmithKline Biologicals; Rixensart, Belgium
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.